What's on this Page
Etanercept Brand Names- Enbrel | ERELZI
What is Etanercept
Etanercept is a subcutaneously administered tumor necrosis factor (TNF) blocker that is a soluble TNF receptor.
Like other TNF blockers, etanercept is useful in a variety of inflammatory disorders.
In adults with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) the drug improves clinical signs and symptoms, inhibits the radiographic progression of structural joint damage, and improves physical function; in adults with ankylosing spondylitis (AS), the drug improves clinical signs and symptoms of active disease.
For adult RA, PsA, or AS, etanercept may be used as monotherapy; the drug may also be used with other disease-modifying antirheumatic agents (DMARDs).
The ideal combination of therapy for individual patients with inflammatory arthritis conditions is determined by treat to target strategies and severity of disease.
For PsA, TNF-blockers are considered a first-line treatment, even in treatment-naive patients.
In pediatric patients 2 years and older, etanercept reduces signs and symptoms of moderately to severely active polyarticular juvenille idiopathic arthritis (JIA) in patients intolerant or refractory to methotrexate.
Etanercept is beneficial for adult and pediatric patients 4 years or older with chronic moderate to severe plaque psoriasis; TNF-blockers may be used as first-line systemic treatments alone or in combination with other therapies.
Etanercept does not appear to be effective for Wegener’s granulomatosis.
Etanercept is not effective for treating inflammatory bowel diseases (IBD); cases of new IBD have been reported with etanercept use.
As with other TNF-blockers, etanercept product labels include boxed warnings regarding the risk of tuberculosis, other infections, and malignancy
Indications
- ankylosing spondylitis
- juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)
- psoriasis
- psoriatic arthritis
- rheumatoid arthritis
For reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA)
Side Effects
- anemia
- angioedema
- antibody formation
- aplastic anemia
- aseptic meningitis
- candidiasis
- chest pain (unspecified)
- diarrhea
- ecchymosis
- elevated hepatic enzymes
- erythema multiforme
- fever
- Guillain-Barre syndrome
- heart failure
- hepatitis
- hepatitis B exacerbation
- infection
- inflammatory bowel disease
- influenza
- injection site reaction
- interstitial lung disease
- leukemia
- leukopenia
- lupus-like symptoms
- lymphadenopathy
- lymphoma
- Merkel cell carcinoma
- myelitis
- neutropenia
- new primary malignancy
- ocular inflammation
- optic neuritis
- pancytopenia
- paresthesias
- pharyngitis
- pruritus
- psoriaform rash
- psoriasis
- rash
- seizures
- sinusitis
- skin cancer
- Stevens-Johnson syndrome
- thrombocytopenia
- toxic epidermal necrolysis
- urticaria
- uveitis
- vasculitis
Monitoring Parameters
- hepatitis B serology
- plasma hepatitis C RNA
- plasma HIV RNA
- skin cancer screening exam
- tuberculin skin test
Contraindications
- autoimmune disease
- bone marrow suppression
- breast-feeding
- children
- corticosteroid therapy
- diabetes mellitus
- fungal infection
- geriatric
- heart failure
- hematological disease
- hepatitis
- hepatitis B exacerbation
- hepatitis C infection
- HIV serum status
- immunosuppression
- infants
- infection
- latex hypersensitivity
- leukemia
- lymphoma
- melanoma
- multiple sclerosis
- mycobacterial infection
- neonates
- neurological disease
- new primary malignancy
- pregnancy
- seizure disorder
- seizures
- sepsis
- skin cancer
- surgery
- tuberculosis
- vaccination
- varicella
- viral infection
- Wegener’s granulomatosis
Interactions
- Abatacept
- Adalimumab
- Anakinra
- Baricitinib
- Belimumab
- Canakinumab
- Certolizumab pegol
- Cyclophosphamide
- Golimumab
- Infliximab
- Live Vaccines
- Natalizumab
- Rabies Vaccine
- Rilonacept
- Rituximab
- Rituximab; Hyaluronidase
- Sarilumab
- Sulfasalazine
- Tocilizumab
- Tofacitinib
- Tuberculin Purified Protein Derivative, PPD
- Upadacitinib
- Vedolizumab
